BIOMARIN PHARMACEUTICAL INC. overview

BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024 PR Newswire SAN RAFAEL, Calif., Nov. 16, 2024 SAN RAFAEL, Calif. , Nov. 16, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced positive and consistent results from multiple real-world evidence studies of VOXZOGO ® (vosoritide) in children with achondroplasia....

BioMarin to Participate in Three Upcoming Investor Conferences PR Newswire SAN RAFAEL, Calif., Nov. 6, 2024 UBS Global Healthcare Conference on November 12 at 11:00 am PST Jefferies London Healthcare Conference on November 19 at 9:00 am GMT 7th Annual Evercore ISI HealthCONx Conference on December 4 at 7:00 am PST SAN RAFAEL, Calif. , Nov. 6, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at three upcoming investor conferences. An...

BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook PR Newswire SAN RAFAEL, Calif., Oct. 29, 2024 Third Quarter 2024 Total Revenues of $746 million (+28% Y/Y and +32% at Constant Currency Y/Y); Year-to-date 2024 Total Revenues of $2.11 billion (+19% Y/Y and +23% at Constant Currency Y/Y) During the Quarter, Strong Demand Drove 54% Y/Y Revenue Growth for VOXZOGO ® During the Quarter, Revenues from...

BioMarin to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Tuesday, October 29, 2024, at 4:30pm ET PR Newswire SAN RAFAEL, Calif., Oct. 16, 2024 SAN RAFAEL, Calif. , Oct. 16, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy , President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Tuesday, October 29, 2024 , at 4:30 p.m. ET to discuss third quarter 2024 financial results and...

BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® (vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia at 2024 International Skeletal Dysplasia Society Meeting PR Newswire SAN RAFAEL, Calif., Sept. 18, 2024 Results from Ongoing CANOPY Clinical Program for VOXZOGO Showcase Impact of C-Type Natriuretic Peptide (CNP) as Master Regulator of Growth-Related Development Across Multiple Genetic Skeletal...

BioMarin Holds Investor Day; Provides New Corporate Strategy and Introduces 2027 Financial Guidance PR Newswire NEW YORK, Sept. 4, 2024 NEW YORK , Sept. 4, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) hosted an Investor Day earlier today, where President and Chief Executive Officer Alexander Hardy and other members of BioMarin's leadership team provided an overview of the company's new corporate strategy to deliver sustained value creation and introduced longer-term Total...

BioMarin to Host Investor Day Today at 10:30 a.m. Eastern Time PR Newswire NEW YORK, Sept. 4, 2024 NEW YORK , Sept. 4, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will host its Investor Day today in New York. The event begins at 10:30 a.m. Eastern Time and can be accessed virtually here . Led by President and Chief Executive Officer Alexander Hardy , the event will feature presentations from BioMarin's leadership team as they introduce strategic priorities that underscore...

BioMarin to Present at the 22nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5 at 7:45 AM PT / 10:45 AM ET in New York, NY PR Newswire SAN RAFAEL, Calif., Aug. 29, 2024 SAN RAFAEL, Calif. , Aug. 29, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Brian Mueller , Executive Vice President, Chief Financial Officer of BioMarin will present at the 22 nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5, 2024...